FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 352:534-535 February 10, 2005 Number 6 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

The majority of the financial support for continuing medical education (CME) in the United States comes from drug companies and other commercial entities (see graph).¹ Total commercial support more than tripled between 1998 and 2003 — from $302 million to $971 million. CME should aim to improve health care and should be totally independent of commercial interests, but there are long-standing concerns that it often involves marketing as well as education.² For example, about 100 accredited U.S. providers of CME are for-profit medical education and communication companies, or MECCs. They are hired by pharmaceutical firms to organize meetings, find . . . [Full Text of this Article]

Source Information

Dr. Steinbrook is a national correspondent for the Journal.

This article has been cited by other articles:

• Steinbrook, R. (2008). Financial Support of Continuing Medical Education. JAMA 299: 1060-1062 [Full Text]  
• Steinman, M. A., Baron, R. B. (2007). Is continuing medical education a drug-promotion tool?: YES. cfp 53: 1650-1653 [Full Text]  
• Steinman, M. A., Baron, R. B. (2007). La formation medicale continue est-elle un outil de promotion pharmaceutique?: OUI. cfp 53: 1654-1657 [Full Text]  
• Tonelli, M. R. (2007). Conflict of Interest in Clinical Practice. Chest 132: 664-670 [Abstract] [Full Text]  
• Steinman, M. A., Chren, M.-M., Landefeld, C. S., Bero, L. A. (2007). The Promotion of Gabapentin. ANN INTERN MED 146: 313-314 [Full Text]  
• Steinman, M. A., Bero, L. A., Chren, M.-M., Landefeld, C. S. (2006). Narrative Review: The Promotion of Gabapentin: An Analysis of Internal Industry Documents. ANN INTERN MED 145: 284-293 [Abstract] [Full Text]  
• Becker, G. J. (2006). Financial Relationships with Industry and Device Research Involving Non-Food and Drug Administration-approved Use: A Perspective.. Radiology 239: 626-628 [Full Text]  
• Brown, S. D., Daly, J. C., Kalish, L. A., McDaniel, S. A. (2006). Financial Disclosures of Scientific Papers Presented at the 2003 RSNA Annual Meeting: Association with Reporting of Non-Food and Drug Administration-approved Uses of Industry Products. Radiology 239: 849-855 [Abstract] [Full Text]  
• Parles, K. (2005). Regarding "Recommendations for Zoledronic Acid Treatment of Patients with Bone Metastases". The Oncologist 10: 304-305 [Full Text]